Federal Circuit Clarifies Permissible Scope of IPR Replies and Analogous Prior Art Tests

In Corephotonics, Ltd. v. Apple, Inc., No. 2022-1340, 2022-1341 (Fed. Cir. Oct. 16, 2023), the Court of Appeals for the Federal Circuit (“Federal…

Related Keywords

,Mylan Pharms ,Biomarin Pharm ,Sanofi Aventis Deutschland Gmb ,Sanofi Aventis ,Firepass Corp ,Nuvasive Inc ,Apple Inc ,Anacor Pharms Inc ,Alere Inc ,Psys Inc ,Patent Office ,Corephotonics Ltd ,Regarding Corephotonics ,Federal Circuit ,Appeals Board ,Challenged Patents ,Anacor Pharms ,Rembrandt Diagnostics ,Genzyme Therapeutic ,Sanofi Aventis Deutschland Gmbh ,Law ,Lawyers ,Legal ,Aw Firms ,Aw Updates ,Egal Updates ,Egal Developments ,Aw Developments ,Egal Newsletters ,Egal Current Awareness ,Deals ,Egal Advisers ,Egal Advisors ,Egal Directory ,Sa ,Litigation ,